210 related articles for article (PubMed ID: 27358436)
21. [Non-vitamin K oral antagonist no more new!].
Stępińska J; Wożakowaka-Kapłon B; Pruszczyk P; Kalarus Z
Kardiol Pol; 2014; 72(9):854-5. PubMed ID: 25231426
[No Abstract] [Full Text] [Related]
22. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
Haft JI
Clin Appl Thromb Hemost; 2013 Jun; 19(3):241-8. PubMed ID: 22952215
[TBL] [Abstract][Full Text] [Related]
23. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
[TBL] [Abstract][Full Text] [Related]
24. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
Ieko M
Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540
[TBL] [Abstract][Full Text] [Related]
25. Outpatient management of oral anticoagulation in atrial fibrillation.
Manning JA
Crit Care Nurs Clin North Am; 2013 Dec; 25(4):481-7, vi. PubMed ID: 24267284
[TBL] [Abstract][Full Text] [Related]
26. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Hajhosseiny R; Sabir I; Lip GY
Hosp Pract (1995); 2014 Oct; 42(4):153-62. PubMed ID: 25502139
[TBL] [Abstract][Full Text] [Related]
27. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
28. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
Divisón Garrote JA; Escobar Cervantes C
Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
[No Abstract] [Full Text] [Related]
29. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Fanikos J; Burnett AE; Mahan CE; Dobesh PP
Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
[TBL] [Abstract][Full Text] [Related]
30. Stroke prevention in atrial fibrillation: do we still need warfarin?
Diener HC; Weber R; Lip GY; Hohnloser SH
Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
[TBL] [Abstract][Full Text] [Related]
31. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Arepally GM; Ortel TL
Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
[TBL] [Abstract][Full Text] [Related]
32. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
[No Abstract] [Full Text] [Related]
34. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
35. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
36. Which drug should we use for stroke prevention in atrial fibrillation?
Lau YC; Lip GY
Curr Opin Cardiol; 2014 Jul; 29(4):293-300. PubMed ID: 25029448
[TBL] [Abstract][Full Text] [Related]
37. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
38. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomic testing and response to warfarin.
Wu AH
Lancet; 2015 Jun; 385(9984):2231-2. PubMed ID: 25769360
[No Abstract] [Full Text] [Related]
40. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
